Why the study?
Does NCX 4016 provide effective anti-atherothrombotic activity with reduced gastric toxicity compared to traditional aspirin?
Does NCX 4016 provide effective anti-atherothrombotic activity with reduced gastric toxicity compared to traditional aspirin?
NCX 4016, a novel NO-releasing aspirin, shows promising preclinical and early clinical anti-atherothrombotic effects with reduced gastric toxicity, warranting long-term outcome trials.
No takes yet. Share an insight, caveat, or question.
Should not yet change aspirin use; leaves open whether NCX 4016 improves long-term outcomes versus aspirin.
Gresele et al. (2006) studied this question.